SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

elritercept

KROS·Keros Therapeutics, Inc.
MIXED
Drug Impact Rating4/10
Trial Phase
Phase 3 (MDS); Phase 3 planned (myelofibrosis)
Time to Market
Unknown — several years: the Phase 3 ELRiSE MDS trial (elritercept vs epoetin alfa in low-risk MDS) only began dosing patients in July 2026, and the myelofibrosis Phase 3 is planned but not yet underway; no regulatory filing or PDUFA exists.
Why 4/10
No hard, dated binary inside ~12 months: Phase 3 ELRiSE MDS only dosed its first patient in July 2026 (a top-line readout is years away), the myelofibrosis Phase 3 has not started, and there is no PDUFA — so this mid-stage, partner-driven program scores 4 on the default band.
Actionable Insight ◆ MIXED

Watch KROS's Q2 2026 earnings (before market open, Aug 4, 2026) and any timing update on the 25% shareholder distribution of the $20M Takeda milestone. The next real value inflection — a Phase 3 readout — is years out, so near-term moves will be driven by Takeda milestones, financing/dilution news (no approved product; cash burn continuing), and execution on the ELRiSE MDS enrollment.

Price Chart

Loading chart...

Executive Summary

Elritercept is Keros Therapeutics' lead hematology drug, licensed globally to Takeda under a deal effective January 2025 that brought a $200M upfront payment and eligibility for $1.1B+ in milestones plus tiered royalties. The pivotal Phase 3 ELRiSE MDS trial (vs epoetin alfa in low-risk MDS) dosed its first patient in July 2026 — triggering a $20M milestone, 25% of which Keros plans to distribute to stockholders — and Takeda is planning a Phase 3 in myelofibrosis. KROS trades near its 52-week low (~$10.07 vs $22.55 high) with a mean analyst price target of ~$21.83, but remains pre-revenue with no near-term binary: Phase 3 readouts are years out.

How It Works

A biologic (an engineered protein designed to trap certain TGF-beta-family signaling molecules) aimed at removing signals that suppress blood-cell production, so the body can make more red blood cells (and platelets). The goal is to relieve anemia in bone-marrow disorders such as myelodysplastic syndromes (MDS) and myelofibrosis — the same general disease area as older anemia treatments like epoetin alfa, which is the comparator in the Phase 3 trial.

Trial Status

Phase 3 ELRiSE MDS (open-label, randomized elritercept vs epoetin alfa in low-risk myelodysplastic syndromes) dosed its first patient in July 2026, triggering a $20M development milestone from Takeda; per Q1 2026 company commentary, Takeda plans to advance elritercept into a Phase 3 trial in myelofibrosis. Prior Phase 2 data supported Takeda's $200M-upfront global license (deal effective Jan 16, 2025).

The Two-Sided Case

▲ Bull Case5
Takeda validation is concrete: a $20M development milestone was triggered by first patient dosing in the Phase 3 ELRiSE MDS trial (8-K filed July 30, 2026), on top of a $200M upfront from the global license — evidence the partner judged Phase 2 data strong enough to fund a pivotal program.
Pipeline momentum: ELRiSE MDS is now enrolling and Takeda plans to advance elritercept into a Phase 3 myelofibrosis trial, per Q1 2026 company commentary.
Keros expects to distribute 25% of the net cash proceeds of the $20M milestone to stockholders — a tangible near-term capital return (8-K analysis).
Street view is positive: consensus shows 9 Buy/Strong Buy vs 0 Sell, with a mean price target of ~$21.83 (median $20, high $30) versus a ~$10.07 share price — roughly 98.6% implied upside per the local analyst snapshot.
Balance sheet: ~$287.4M cash at FY2025 year-end with runway into H1 2028, plus up to $1.1B+ in Takeda milestones ahead.
▼ Bear Case5
No near-term dated catalyst: the Phase 3 MDS readout is likely several years away, the myelofibrosis Phase 3 hasn't started, and there is no PDUFA — the stock has no imminent binary to re-rate on.
Pre-revenue and bleeding cash: Q1 2026 net loss of $23.7M (EPS -$1.21, a miss vs ~-$0.92 consensus) and revenue of just $367K, versus $211.2M in Q1 2025 that was one-time Takeda license income — a setup that can invite future dilution.
Full dependence on a partner: development and commercialization rest with Takeda, so timelines and milestone payments are outside Keros' control; the 8-K analysis itself flags Phase 3 failure risk and Takeda dependence.
Weak tape and execution noise: shares sit near the 52-week low ($9.69–$22.55 range) and the CFO resigned effective Aug 3, 2026 (8-K filed July 22, 2026), with an interim CFO appointed; Q2 2026 earnings land Aug 4, 2026.
Competitive standard of care: low-risk MDS anemia is an established treatment market (the Phase 3 comparator is epoetin alfa), so elritercept must beat entrenched therapy to win.

Upcoming Catalysts

  • Q2 2026 earnings before market open on Aug 4, 2026 (event calendar) — first look at the quarter after the ELRiSE milestone
  • Timing/amount of the 25% stockholder distribution of the $20M Takeda milestone net proceeds
  • Takeda updates on initiating the Phase 3 myelofibrosis trial for elritercept
  • ELRiSE MDS enrollment progress and any further Takeda milestone triggers (potential $1.1B+ remaining)
  • Search for a permanent CFO after the Aug 2026 resignation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Keros Therapeutics, Inc. 8-K KROS ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov